Nifedipine
NDC Package 16590-948-30

11-digit billing NDC: 16590094830

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Nifedipine is vasospastic AnginaNifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. Marketed by Stat Rx Usa Llc, this product is identified by NDC 16590-948 and is authorized under FDA application ANDA090649.

Identification & Billing

NDC Package Code
16590-948-30
Package Description
30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
16590094830
RxNorm Crosswalk
  • RxCUI: 1812013 - NIFEdipine 60 MG Osmotic 24HR Extended Release Oral Tablet
  • RxCUI: 1812013 - Osmotic 24 HR nifedipine 60 MG Extended Release Oral Tablet
  • RxCUI: 1812013 - nifedipine 60 MG Osmotic 24 HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Nifedipine
Dosage Form
-
Usage Information
Vasospastic AnginaNifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers.Chronic Stable Angina (Classical Effort-Associated Angina)Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents.In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to 8 weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete.Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (See WARNINGS.)HypertensionNifedipine extended-release tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.

Regulatory & Marketing

Labeler Name
Stat Rx Usa Llc
FDA Application #
ANDA090649
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-28-2011
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (16590-948). Click a package code to view its specific billing and regulatory data.

60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-948-30 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Nifedipine, labeled by Stat Rx Usa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa Llc on June 28, 2011. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590094830. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-948-30
11-Digit CMS (5-4-2)
16590-0948-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.